Free Trial
NASDAQ:IRON

Disc Medicine Q2 2025 Earnings Report

Disc Medicine logo
$59.65 -0.01 (-0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$59.75 +0.10 (+0.17%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Disc Medicine EPS Results

Actual EPS
-$1.58
Consensus EPS
-$1.17
Beat/Miss
Missed by -$0.41
One Year Ago EPS
N/A

Disc Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Disc Medicine Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Disc Medicine's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Disc Medicine Earnings Headlines

Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $95.73
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
Disc Medicine (IRON) Receives a Buy from TD Cowen
Disc Medicine (IRON) Receives a Buy from Truist Financial
See More Disc Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email.

About Disc Medicine

Disc Medicine (NASDAQ:IRON), together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

View Disc Medicine Profile

More Earnings Resources from MarketBeat